Company intelligence / Profile preview

RedGene

Ownership: Private
Development stage: Other

Overview

RedGene is a South Korea-based biotechnology company founded in 2022, specializing in preclinical pharmaceutical development aimed at both human and companion animal healthcare. The company has raised $490K through grants, with support from investors such as TIPS Program and Scale Up Partners. Its scientific advisory board includes professors from leading Korean medical institutions. Specific clinical results or pipeline details are not publicly disclosed.

Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on RedGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RedGene.

Explore the full profile